Literature DB >> 2550614

Effects of opioid agonists on sympathetic and parasympathetic transmission to the dog heart.

T Musha1, E Satoh, H Koyanagawa, T Kimura, S Satoh.   

Abstract

Effects of leu- and met-enkephalin, pentazocine and morphine on negative or positive chronotropic response to vagal nerve stimulation or cardiac sympathetic nerve stimulation were examined in anesthetized dogs in order to determine whether opioid receptors modulate vagal and sympathetic transmission. Leu- and met-enkephalin (10-100 micrograms/kg i.v.) and pentazocine (100-1000 micrograms/kg i.v.) inhibited bradycardic response to vagal nerve stimulation (1-4 Hz) in a dose-dependent manner. Morphine (300 and 1000 micrograms/kg i.v.) did not affect vagal bradycardia. The inhibitory effect of leu-enkephalin (30 micrograms/kg) and pentazocine (300 micrograms/kg) was effectively antagonized by naloxone (1000 micrograms/kg i.v.). Bradycardic response to intracoronary injection of methacholine (0.1, 0.3 and 1 microgram) into the right coronary artery was unaffected by leu-enkephalin (30 micrograms/kg). On the other hand, leu-enkephalin and pentazocine did not modify tachycardic response to sympathetic nerve stimulation (1-8 Hz). Morphine attenuated sympathetic tachycardia only slightly. These results suggest that presynaptic opioid receptors, probably delta type, are present in the vagus nerves, and that the activation of opioid receptors inhibit vagal transmission to the dog heart. In contrast, the presence of opioid receptors in the cardiac sympathetic nerves is not evident.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550614

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  Peripheral modulation of learning and memory: enkephalins as a model system.

Authors:  G Schulteis; J L Martinez
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Low-dose morphine reduces pain perception and blood pressure, but not muscle sympathetic outflow, responses during the cold pressor test.

Authors:  Joseph C Watso; Luke N Belval; Frank A Cimino; Bonnie D Orth; Joseph M Hendrix; Mu Huang; Elias Johnson; Josh Foster; Carmen Hinojosa-Laborde; Craig G Crandall
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-06-17       Impact factor: 5.125

3.  Low-dose morphine reduces tolerance to central hypovolemia in healthy adults without affecting muscle sympathetic outflow.

Authors:  Joseph C Watso; Luke N Belval; Frank A Cimino; Bonnie D Orth; Joseph M Hendrix; Mu Huang; Elias Johnson; Josh Foster; Carmen Hinojosa-Laborde; Craig G Crandall
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-04-22       Impact factor: 5.125

Review 4.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

5.  fMRI functional connectivity of the periaqueductal gray in PTSD and its dissociative subtype.

Authors:  Sherain Harricharan; Daniela Rabellino; Paul A Frewen; Maria Densmore; Jean Théberge; Margaret C McKinnon; Allan N Schore; Ruth A Lanius
Journal:  Brain Behav       Date:  2016-09-20       Impact factor: 2.708

6.  Impact of individual and treatment characteristics on wearable sensor-based digital biomarkers of opioid use.

Authors:  Brittany P Chapman; Bhanu Teja Gullapalli; Tauhidur Rahman; David Smelson; Edward W Boyer; Stephanie Carreiro
Journal:  NPJ Digit Med       Date:  2022-08-22

7.  Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block.

Authors:  Phu N Tran; Jiansong Sheng; Aaron L Randolph; Claudia Alvarez Baron; Nicolas Thiebaud; Ming Ren; Min Wu; Lars Johannesen; Donna A Volpe; Dakshesh Patel; Ksenia Blinova; David G Strauss; Wendy W Wu
Journal:  PLoS One       Date:  2020-11-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.